Tag Archives: Mirati Therapeutics

The EVP, Chief Scientific Officer of Mirati Therapeutics is Exercising Options

Yesterday it was reported that the EVP, Chief Scientific Officer of Mirati Therapeutics (MRTX – Research Report), Jamie Christensen, exercised options to buy 5,169 MRTX shares at $17.41 a share, for a total transaction value of $89.99K. This recent transaction

Jefferies Reiterates Their Hold Rating on Mirati Therapeutics (MRTX)

Jefferies analyst Maury Raycroft reiterated a Hold rating on Mirati Therapeutics (MRTX – Research Report) on November 11 and set a price target of $37. The company’s shares closed yesterday at $37.23. According to TipRanks.com, Raycroft is a 3-star analyst

Mirati Therapeutics (MRTX) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Edward White maintained a Buy rating on Mirati Therapeutics (MRTX – Research Report) today and set a price target of $65. The company’s shares closed on Friday at $39.56. White said: “We derive our $65 price target

Mirati Therapeutics (MRTX) Receives a Buy from Oppenheimer

In a report released yesterday, Leah R. Cann from Oppenheimer maintained a Buy rating on Mirati Therapeutics (MRTX – Research Report), with a price target of $57. The company’s shares closed yesterday at $39.15. Cann observed: “Loss per share was

Analysts Are Bullish on These Healthcare Stocks: Mirati Therapeutics (MRTX), Incyte Corp (INCY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mirati Therapeutics (NASDAQ:MRTX) and Incyte Corp (NASDAQ:INCY) with bullish sentiments. Mirati Therapeutics (MRTX) In a report released today, Leah R. Cann from

Mirati Therapeutics (MRTX) Gets a Buy Rating from Oppenheimer

In a report released yesterday, Leah R. Cann from Oppenheimer maintained a Buy rating on Mirati Therapeutics (NASDAQ: MRTX), with a price target of $62. The company’s shares closed on Friday at $40.01. Cann noted: “The data presented at ESMO